Topics

Human medicines European public assessment report (EPAR): Talmanco (previously Tadalafil Generics), tadalafil, Hypertension, Pulmonary, Date of authorisation: 09/01/2017, Revision: 4, Status: Authorised

10:10 EST 15 Jan 2020 | European Medicines Agency

Human medicines European public assessment report (EPAR): Talmanco (previously Tadalafil Generics), tadalafil, Hypertension, Pulmonary, Date of authorisation: 09/01/2017, Revision: 4, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Talmanco (previously Tadalafil Generics), tadalafil, Hypertension, Pulmonary, Date of authorisation: 09/01/2017, Revision: 4, Status: Authorised

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Talmanco (previously Tadalafil Generics), tadalafil, Hypertension, Pulmonary, Date of authorisation: 09/01/2017, Revision: 4, Status: Authorised"

Quick Search

Relevant Topics

Erectile Dysfunction
Erectile dysfunction (ED or impotence) is the inability to get and maintain an erection that is sufficient for satisfactory sexual intercourse, and affects half of all men between the ages of 40 to 70. The causes of ED can be both physical and psycholo...

Pulmonary Hypertension
Pulmonary arterial hypertension (PAH) is a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs of affected individuals. Symptoms can range from mild breathles...

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...